We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $120.78, demonstrating a +1.1% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
Shares of the specialty chemicals company witnessed a loss of 25.5% over the previous month, trailing the performance of the Basic Materials sector with its loss of 10.7%, and the S&P 500's gain of 0.32%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2026. The company's earnings per share (EPS) are projected to be $3.21, reflecting a 2818.18% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.52 billion, reflecting a 14.53% rise from the equivalent quarter last year.
ALB's full-year Zacks Consensus Estimates are calling for earnings of $13.06 per share and revenue of $6.13 billion. These results would represent year-over-year changes of +1753.16% and +19.15%, respectively.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.44% upward. Albemarle presently features a Zacks Rank of #2 (Buy).
From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 9.15. This represents a discount compared to its industry average Forward P/E of 15.01.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Rises As Market Takes a Dip: Key Facts
Albemarle (ALB - Free Report) ended the recent trading session at $120.78, demonstrating a +1.1% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
Shares of the specialty chemicals company witnessed a loss of 25.5% over the previous month, trailing the performance of the Basic Materials sector with its loss of 10.7%, and the S&P 500's gain of 0.32%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2026. The company's earnings per share (EPS) are projected to be $3.21, reflecting a 2818.18% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.52 billion, reflecting a 14.53% rise from the equivalent quarter last year.
ALB's full-year Zacks Consensus Estimates are calling for earnings of $13.06 per share and revenue of $6.13 billion. These results would represent year-over-year changes of +1753.16% and +19.15%, respectively.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.44% upward. Albemarle presently features a Zacks Rank of #2 (Buy).
From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 9.15. This represents a discount compared to its industry average Forward P/E of 15.01.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.